Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors

Journal of Peptide Science

Volumn 13, Issue 5, 2007, Pages 348-353

  Pakkala, Mikka ^a   Hekim, Can ^b   Soininen, Pasi ^a   Leinonen, Jari ^b   Koistinen, Hannu ^b   Weisell, Janne ^a   Stenman, Ulf Håkan ^b   Vepsäläinen, Jouko ^a   Närvänen, Ale ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cancer; Human kallikrein 2; Resistance against proteolysis; Stability; Synthetic peptides

Indexed keywords

CYCLOPEPTIDE INHIBITOR; CYSTEINE; KALLIKREIN; KALLIKREIN 2; KALLIKREIN 2 PEPTIDE INHIBITOR; PEPTIDE DERIVATIVE; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY ANALYSIS;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; HUMANS; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE KALLIKREINS;

EID: 34248395596     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.849     Document Type: Article

References (22)

1. Yousef GM, Diamandis EP. An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. Clin. Biochem. 2003; 36: 443-452.
2. Diamandis EP. Prostate specific antigen - its usefulness in clinical medicine. Trends Endocrionlol. Metab. 1998; 9: 310-316.
3. Lilja H, Lilja DR. Early diagnosis and staging. Prostate Cancer Prostatic Dis. 1999; 2: 15-18.
4. Stenman U-H, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin. Cancer Biol. 1999; 9: 83-93.
5. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997; 49: 857-862.
6. Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM. Preorative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002; 62: 5974-5979.
7. Schramm HJ, Nakashima H, Schramm W, Wakayama H, Yamamoto N. HIV-1 reproduction is inhibited by peptides derived frm the N- and C-termini of HIV-1 protease. Biochem. Biophys. Res. Commun. 1991; 179: 847-851.
8. Zhang ZY, Poorman RA, Maggiora LL, Heinrikson RL, Kezdy FJ. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 1991; 266: 15591-15594.
9. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 1999; 17: 768-774.
10. Wolf WC, Evans DM, Chao L, Chao J. A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am. J. Pathol. 2001; 159: 1797-1805.
11. Hekim C, Leinonen J, Närvänen A, Koistinen H, Zhu L, Koivunen E, Väisänen, Stenman U-H. Novel peptide inhibitors of human kallikrein 2 (hK2). J. Biol. Chem. 2006; 281: 12555-12560.
12. Leinonen J, Wu P, Koivunen E, Närvänen A, Stenman U-H. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen. Scand. J. Clin. Lab. Invest. 2000; 233(Suppl. 60): 59-64.
13. Pakkala M, Jylhäsalmi A, Wu P, Leinonen J, Stenman U-H, Santa H, Vepsäläinen J, Peräkylä M, Närvänen A. Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity. J. Pept. Sci. 2004; 10: 439-447.
14. Wu P, Stenman U-H, Pakkala M, Närvänen A, Leinonen J. Separation of enzymatically active and inactive forms of prostate specific antigen (PSA) with peptide affinity chromatography. Prostate 2004; 58: 345-353.
15. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev. 2004; 24: 357-397.
16. Raghothama S, Chaddha M, Balaram P. NMR analysis of a conformational transition in an acyclic peptide. Model system for studying helix unfolding. J. Phys. Chem. 1996; 100: 19666-19671.
17. Wishart DS, Sykes BD, Richards FM. Relationship between nuclear magnetic resonance chemical shift and protein secondary structure. J. Mol. Biol. 1991; 222: 311-333.
18. Wüthrich K. NMR of Proteins and Nucleic Acids. Wiley-Interscience: New York, 1996.
19. Cloutier SM, Chagas JR, Mach J-P, Gygi CM. Leisinger H-J, Deperthes D. Substrate specificity of human kallikrein 2 (hK2) determined by phage display technology. Eur. J. Biochem. 2002; 269: 2747-2754.
20. Clark RJ, Fischer H, Dempster L, Daly NL, Rosengren KJ, Nevin ST, Meunier FA, Adams DJ, Craik DJ. Engineering stable peptide toxins by means of backbone cyclization: stabilization of the α-conotoxin MII. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 13767-13772.
21. Ösapay G, Prokai L, Kim HS, Medzihradszky KF, Coy DH, Liapakis G, Reisine T, Melacini G, Zhu Q, Wang SH, Mattern RH, Goodman M. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. J Med. Chem. 1997; 40: 2241-2251.
22. Weiner RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 2005; 19: 145-163.